EP3848023 - AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.06.2021 Database last updated on 19.07.2024 | |
Former | The international publication has been made Status updated on 14.03.2020 | Most recent event Tooltip | 29.09.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Metabolic and Obese Research Science Corporation 3-49-12, Kamikoide-machi Maebashi-shi, Gunma, 371-0037 / JP | [2021/28] | Inventor(s) | 01 /
MORI, Masatomo c/o Metabolic and Obese Research Science Corporation, 3-49-12, Kamikoide-machi Maebashi-shi, Gunma 371-0037 / JP | [2021/28] | Representative(s) | Moodie, Samantha Laura, et al Mathys & Squire The Shard 32 London Bridge Street London SE1 9SG / GB | [2021/28] | Application number, filing date | 19857203.4 | 03.09.2019 | [2021/28] | WO2019JP34675 | Priority number, date | JP20180164819 | 03.09.2018 Original published format: JP 2018164819 | [2021/28] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020050290 | Date: | 12.03.2020 | Language: | JA | [2020/11] | Type: | A1 Application with search report | No.: | EP3848023 | Date: | 14.07.2021 | Language: | EN | [2021/28] | Search report(s) | International search report - published on: | JP | 12.03.2020 | (Supplementary) European search report - dispatched on: | EP | 27.05.2022 | Classification | IPC: | A61K31/155, A61K9/20, A61K9/48, A61P1/16, A61P3/00, A61P3/04, A61P3/06, A61P3/10, A61P5/50, A61P9/00, A61P9/10, A61P9/12, A61P13/12, A61P19/06, A61P43/00 | [2022/26] | CPC: |
A61K45/06 (EP);
A61K31/155 (EP,US);
A61K9/2009 (EP);
A61K9/2013 (EP);
A61K9/2018 (EP);
A61K9/2027 (EP);
A61K9/2054 (EP);
A61K9/2059 (EP);
A61K9/485 (EP);
A61K9/4858 (EP);
A61K9/4866 (EP);
A61P1/16 (EP,US);
A61P13/12 (EP);
A61P19/06 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61P5/50 (EP);
A61P9/00 (EP);
| C-Set: |
A61K31/155, A61K2300/00 (EP)
|
Former IPC [2021/28] | A61K31/155, A61P1/16, A61P3/00, A61P3/04, A61P3/06, A61P3/10, A61P5/50, A61P9/00, A61P9/10, A61P9/12, A61P13/12, A61P19/06, A61P43/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/28] | Title | German: | LINDERUNGSMITTEL FÜR FETTLEIBIGKEITSBEDINGTE STOFFWECHSELERKRANKUNG | [2021/28] | English: | AMELIORATING AGENT FOR OBESITY-RELATED METABOLIC DISEASE | [2021/28] | French: | AGENT D'AMÉLIORATION POUR MALADIE MÉTABOLIQUE LIÉE À L'OBÉSITÉ | [2021/28] | Entry into regional phase | 01.04.2021 | Translation filed | 01.04.2021 | National basic fee paid | 01.04.2021 | Search fee paid | 01.04.2021 | Designation fee(s) paid | 01.04.2021 | Examination fee paid | Examination procedure | 01.04.2021 | Examination requested [2021/28] | 21.12.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.09.2021 | Renewal fee patent year 03 | 23.09.2022 | Renewal fee patent year 04 | 28.09.2023 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. |